Halozyme Therapeutics, Inc. (FRA:RV7)

Germany flag Germany · Delayed Price · Currency is EUR
55.20
-1.00 (-1.78%)
At close: Dec 4, 2025
19.43%
Market Cap 6.40B
Revenue (ttm) 1.06B
Net Income (ttm) 507.54M
Shares Out n/a
EPS (ttm) 4.04
PE Ratio 12.61
Forward PE 8.36
Dividend n/a
Ex-Dividend Date n/a
Volume 224
Average Volume 91
Open 55.16
Previous Close 56.20
Day's Range 54.44 - 55.20
52-Week Range 42.45 - 66.90
Beta n/a
RSI 34.12
Earnings Date Feb 18, 2026

About Halozyme Therapeutics

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the disper... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1998
Employees 350
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol RV7
Full Company Profile

Financial Performance

In 2024, Halozyme Therapeutics's revenue was $1.02 billion, an increase of 22.44% compared to the previous year's $829.25 million. Earnings were $444.09 million, an increase of 57.71%.

Financial numbers in USD Financial Statements

News

There is no news available yet.